Anti-inflammatory effect of anemarsaponin B isolated from the rhizomes of Anemarrhena asphodeloides in LPS-induced RAW 264.7 macrophages is mediated by negative regulation of the nuclear factor-κB and p38 pathways

Food and Chemical Toxicology

Volumn 47, Issue 7, 2009, Pages 1610-1617

  Kim, Ji Yeon ^a   Shin, Ji Sun ^a   Ryu, Jong Hoon ^a   Kim, Sun Yeou ^a   Cho, Young Wuk ^a   Choi, Jung Hye ^a   Lee, Kyung Tae ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Anemarsaponin B; Cyclooxygenase 2; Inducible nitric oxide synthase; Nuclear factor B; p38 MAP kinase

Indexed keywords

ANEMARSAPONIN B; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; CYTOKINE; DNA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MIXED LINEAGE KINASE 3; SAPONIN DERIVATIVE; SYNAPTOPHYSIN; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANEMARRHENA ASPHODELOIDES; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA BINDING; DRUG ISOLATION; DRUG STRUCTURE; GEL MOBILITY SHIFT ASSAY; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; REPORTER GENE; RHIZOME; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION;

ANEMARRHENA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELL LINE; CYCLOOXYGENASE 2; DINOPROSTONE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLANT ROOTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SAPONINS; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

ANEMARRHENA ASPHODELOIDES; LILIACEAE;

EID: 67349235535     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2009.04.009     Document Type: Article

References (45)

1. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappaB activity through induction of I kappaB synthesis. Science 270 (1995) 286-290
2. Bae G., Yu J.R., Lee J., Chang J., and Seo E.K. Identification of nyasol and structurally related compounds as the active principles from Anemarrhena asphodeloides against respiratory syncytial virus (RSV). Chem. Biodivers. 4 (2007) 2231-2235
3. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat. Immunol. 3 (2002) 20-26
4. Beyaert R., Cuenda A., Vanden Berghe W., Plaisance S., Lee J.C., Haegeman G., Cohen P., and Fiers W. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. 15 (1996) 1914-1923
5. Brancho D., Ventura J.J., Jaeschke A., Doran B., Flavell R.A., and Davis R.J. Role of MLK-3 in the regulation of mitogen-activated protein kinase signaling cascades. Mol. Cell. Biol. 25 (2005) 3670-3681
6. Carter A.B., Knudtson K.L., Monick M.M., and Hunninghake G.W. The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J. Biol. Chem. 274 (1999) 30858-30863
7. Cuenda A., and Rousseau S. P38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 1773 (2007) 1358-1375
8. De Bosscher K., Vanden Berghe W., Vermeulen L., Plaisance S., Boone E., and Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc. Natl. Acad. Sci. USA 97 (2000) 3919-3924
9. Dong J.X., and Han G.Y. A new active steroidal saponin from Anemarrhena asphodeloides. Planta Med. 57 (1991) 460-462
10. Ghosh S., May M.J., and Kopp E.B. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16 (1998) 225-260
11. Hehner S.P., Hofmann T.G., Ushmorov A., Dienz O., Wing-Lan L.I., Lassam N., Scheidereit C., Dröge W., and Schmitz M.L. Mixed-lineage kinase 3 delivers CD3/CD28-derived signals into the I kappaB kinase complex. Mol. Cell. Biol. 20 (2000) 2556-2568
12. Heller R.A., Schena M., Chai A., Shalon D., Bedilion T., Gilmore J., Woolley D.E., and Davis R.W. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc. Natl. Acad. Sci. USA 94 (1997) 2150-2155
13. Iida Y., Oh K.B., Saito M., Matsuoka H., and Kurata H. In vitro synergism between nyasol, an active compound isolated from Anemarrhena asphodeloides, and azole agents against Candida albicans. Planta Med. 66 (2000) 435-438
14. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20 (2002) 197-216
15. Jeong S.J., Higuchi R., Ono M., Kuwano M., Kim Y.C., and Miyamoto T. Cis-hinokiresinol, a norlignan from Anemarrhena asphodeloides, inhibits angiogenic response in vitro and in vivo. Biol. Pharm. Bull. 26 (2003) 1721-1724
16. Kaminska B. MAPK signaling pathways as molecular targets for anti-inflammatory therapy from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 1754 (2005) 253-262
17. Kang Y.J., Kusler B., Otsuka M., Hughes M., Suzuki N., Suzuki S., Yeh W.C., Akira S., Han J., and Jones P.P. Calcineurin negatively regulates TLR-mediated activation pathways. J. Immunol. 179 (2007) 4598-4607
18. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-kappaB activity. Annu. Rev. Immunol. 18 (2000) 621-663
19. Kefaloyianni E., Gaitanaki C., and Beis I. ERK1/2 and p38 MAPK signaling pathways, through MSK1, are involved in NF-kappaB transactivation during oxidative stress in skeletal myoblasts. Cell. Signal. 18 (2006) 2238-2251
20. Kim J.Y., Park S.J., Yun K.J., Cho Y.W., Park H.J., and Lee K.T. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages. Eur. J. Pharmacol. 584 (2008) 175-184
21. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81 (2001) 807-869
22. Lappas M., Permezel M., Georgiou H.M., and Rice G.E. Nuclear factor-kappaB regulation of pro-inflammatory cytokines in human gestational tissues in vitro. Biol. Reprod. 67 (2002) 668-673
23. Lasa M., Brook M., Saklatvala J., and Clark A.R. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol. Cell. Biol. 21 (2001) 771-780
24. Leung I.W., and Lassam N. Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3. J. Biol. Chem. 273 (1998) 32408-32415
25. Meng Z.Y., Zhang J.Y., Xu S.X., and Sugahara K. Steroidal saponins from Anemarrhena asphodeloides and their effects on superoxide generation. Planta Med. 65 (1999) 661-663
26. Miura T., Ichiki H., Iwamoto N., Kato M., Kubo M., Sasaki H., Okada M., Ishida T., Seino Y., and Tanigawa K. Antidiabetic activity of the rhizoma of Anemarrhena asphodeloides and active components, mangiferin and its glucoside. Biol. Pharm. Bull. 24 (2001) 1009-1011
27. Nam N.H. Naturally occurring NF-kappaB inhibitors. Mini Rev. Med. Chem. 6 (2006) 945-951
28. Niwa A., Takeda O., Ishimaru M., Nakamoto Y., Yamasaki K., Kohda H., Nishio H., Segawa T., Fujimura K., and Kuramoto A. Screening test for platelet aggregation inhibitor in natural products. The active principle of Anemarrhenae rhizoma. Yakuga. Zasshi 108 (1988) 555-561
29. Oh J.K., Hyun S.Y., Oh H.R., Jung J.W., Park C., Lee S.Y., Park J.H., Kim S.Y., Kim K.H., Kim Y.K., and Ryu J.H. Effects of Anemarrhena asphodeloides on focal ischemic brain injury induced by middle cerebral artery occlusion in rats. Biol. Pharm. Bull. 30 (2007) 38-43
30. Park H.J., Lee J.Y., Moon S.S., and Hwang B.K. Isolation and anti-oomycete activity of nyasol from Anemarrhena asphodeloides rhizomes. Phytochemistry 64 (2003) 997-1001
31. Perona R., Montaner S., Saniger L., Sánchez-Pérez I., Bravo R., and Lacal J.C. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev. 11 (1997) 463-475
32. Raingeaud J., Whitmarsh A.J., Barrett T., Dérijard B., and Davis R.J. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol. 16 (1996) 1247-1255
33. Ren L.X., Luo Y.F., Li X., and Wu Y.L. Antidepressant activity of sarsasapogenin from Anemarrhena asphodeloides Bunge (Liliaceae). Pharmazie 62 (2007) 78-79
34. Saklatvala J. The p38 MAP-kinase pathway as a therapeutic target in inflammatory disease. Curr. Opin. Pharmacol. 4 (2004) 372-377
35. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., and Lee S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappaB activation. Mutat. Res. 480-481 (2001) 243-268
36. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu. Rev. Immunol. 21 (2003) 335-376
37. Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R., and Lassam N.J. MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6. EMBO J. 15 (1996) 7026-7035
38. Vanden Berghe W., Plaisance S., Boone E., De Bosscher K., Schmitz M.L., Fiers W., and Haegeman G. P38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273 (1998) 3285-3290
39. Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., and Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 22 (2003) 1313-1324
40. Won J.H., Im H.T., Kim Y.H., Yun K.J., Park H.J., Choi J.W., and Lee K.T. Anti-inflammatory effect of buddlejasaponin IV through the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-kappaB inactivation. Brit. J. Pharmacol. 148 (2006) 216-225
41. Yamamoto Y., and Gaynor R.B. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 107 (2001) 135-142
42. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998) 77-80
43. Zhang G., and Ghosh S. Toll-like receptor-mediated NF-kappaB activation: a phylogene tically conserved paradigm in innate immunity. J. Clin. Invest. 107 (2001) 13-19
44. Zhao D., and Pothoulakis C. Rho GTPases as therapeutic targets for the treatment of inflammatory diseases. Exp. Opin. Ther. Targets 7 (2003) 583-592
45. Zhong J., and Kyriakis J.M. Dissection of a signaling pathway by which pathogen-associated molecular patterns recruit the JNK and p38 MAPKs and trigger cytokine release. J. Biol. Chem. 282 (2007) 24246-24254